JP2021534188A5 - - Google Patents

Info

Publication number
JP2021534188A5
JP2021534188A5 JP2021507982A JP2021507982A JP2021534188A5 JP 2021534188 A5 JP2021534188 A5 JP 2021534188A5 JP 2021507982 A JP2021507982 A JP 2021507982A JP 2021507982 A JP2021507982 A JP 2021507982A JP 2021534188 A5 JP2021534188 A5 JP 2021534188A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
composition according
cancer
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021507982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046852 external-priority patent/WO2020037225A1/en
Publication of JP2021534188A publication Critical patent/JP2021534188A/ja
Publication of JP2021534188A5 publication Critical patent/JP2021534188A5/ja
Ceased legal-status Critical Current

Links

JP2021507982A 2018-08-17 2019-08-16 NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法 Ceased JP2021534188A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862719189P 2018-08-17 2018-08-17
US62/719,189 2018-08-17
US201862733380P 2018-09-19 2018-09-19
US62/733,380 2018-09-19
US201962808376P 2019-02-21 2019-02-21
US62/808,376 2019-02-21
US201962854701P 2019-05-30 2019-05-30
US62/854,701 2019-05-30
PCT/US2019/046852 WO2020037225A1 (en) 2018-08-17 2019-08-16 Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021534188A JP2021534188A (ja) 2021-12-09
JP2021534188A5 true JP2021534188A5 (cg-RX-API-DMAC7.html) 2022-08-15

Family

ID=67841175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507982A Ceased JP2021534188A (ja) 2018-08-17 2019-08-16 NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法

Country Status (12)

Country Link
US (2) US11407825B2 (cg-RX-API-DMAC7.html)
EP (1) EP3836972A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021534188A (cg-RX-API-DMAC7.html)
KR (1) KR20210049122A (cg-RX-API-DMAC7.html)
CN (1) CN113194999A (cg-RX-API-DMAC7.html)
AU (1) AU2019320818A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002747A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109790A1 (cg-RX-API-DMAC7.html)
IL (1) IL280867A (cg-RX-API-DMAC7.html)
MX (1) MX2021001924A (cg-RX-API-DMAC7.html)
TW (1) TW202035452A (cg-RX-API-DMAC7.html)
WO (1) WO2020037225A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JP2021534188A (ja) * 2018-08-17 2021-12-09 メルサナ セラピューティクス インコーポレイテッド NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
TW202308649A (zh) * 2021-05-03 2023-03-01 美商梅爾莎納醫療公司 用於治療卵巢癌之卡鉑與靶向NaPi2b之抗體聚合物-藥物共軛體的組合療法
US20230338569A1 (en) * 2021-09-09 2023-10-26 Mersana Therapeutics, Inc. NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER
KR20250089528A (ko) * 2022-10-18 2025-06-18 투불리스 게엠베하 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도
CN122122183A (zh) * 2023-10-19 2026-05-29 酵活英属哥伦比亚有限公司 抗napi2b抗体-药物缀合物和使用方法
KR102764613B1 (ko) 2024-03-28 2025-02-12 한양대학교 에리카산학협력단 NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
CH694588A5 (de) 1999-02-09 2005-04-15 Hoffmann La Roche Menschliche intestinale Npt2B.
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
AU2003219665A1 (en) 2002-01-15 2003-07-30 Board Of Regents, The University Of Texas System Napi type iib polypeptides and methods for making and using same
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
EP2076286B1 (en) 2006-10-25 2016-03-09 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption using an anti-npt2b antibody
EP2250201B1 (en) 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
JP5370826B2 (ja) 2009-04-20 2013-12-18 株式会社パソロジー研究所 癌の組織型を判別するカクテル抗体、判別キット及び判別方法
TWI507524B (zh) 2009-11-30 2015-11-11 建南德克公司 診斷及治療腫瘤之組合物及方法
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5827326B2 (ja) 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2717916B1 (en) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
WO2015054659A1 (en) * 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9808528B2 (en) * 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
CA2969689A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
WO2017068097A1 (en) 2015-10-23 2017-04-27 Roche Diagnostics Gmbh Methods of identifying an individual as to be treated by chemotherapy based on marker molecules and related uses
US10287259B2 (en) 2016-03-14 2019-05-14 The Penn State Research Foundation Selenazolidine and thiazolidine compounds for treating cancer and other diseases
BR112018068461A2 (pt) * 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
EP3685166A2 (en) 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
JP2021534188A (ja) * 2018-08-17 2021-12-09 メルサナ セラピューティクス インコーポレイテッド NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法

Similar Documents

Publication Publication Date Title
US10849899B2 (en) Combination therapy comprising Varlitinib and an anticancer agent
JP2025129187A5 (cg-RX-API-DMAC7.html)
AU2015249633B2 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
TWI795347B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
JP2023511595A5 (cg-RX-API-DMAC7.html)
JP2023109780A (ja) Her2二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品
JP2018527383A5 (cg-RX-API-DMAC7.html)
WO2017087280A1 (en) Methods of treating her2-positive cancer
JP6255086B2 (ja) 癌のための併用療法
JP2022519273A5 (cg-RX-API-DMAC7.html)
JP2023539589A5 (cg-RX-API-DMAC7.html)
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
WO2025103377A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
JP2025517908A5 (cg-RX-API-DMAC7.html)
JP6822980B2 (ja) Her2陽性転移性乳癌の治療方法
JP2022531894A5 (cg-RX-API-DMAC7.html)
CN120456895A (zh) 使用结合egfr的抗体与细胞毒性药物的组合的癌症治疗
CN120731228A (zh) 肺癌的组合疗法
CN119278053A (zh) 用于治疗子宫恶性肿瘤的药物组合
JPWO2022270523A5 (cg-RX-API-DMAC7.html)
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
JPWO2022019259A5 (cg-RX-API-DMAC7.html)
JP7757339B2 (ja) トラスツズマブ エムタンシンを用いて残存乳癌を治療する方法
WO2025055589A1 (en) Methods of treating cervical cancer using anti-her2 antibody-drug conjugates
CN119607196A (zh) 抗lag-3抗体与抗pd-1抗体的应用